Striatal Glutathione in First-episode Psychosis Patients Measured In Vivo with Proton Magnetic Resonance Spectroscopy. Academic Article uri icon

Overview

abstract

  • Deficits of brain glutathione (GSH), the most abundant and primary antioxidant in living tissue, and associated redox imbalance are postulated to be implicated in schizophrenia. This pilot clinical study compared the levels of striatal GSH, measured in vivo with proton magnetic resonance spectroscopy (1H MRS) at 3T, in 10 drug-naïve, first-episode psychosis (FEP) patients with those in 9 matched healthy control subjects. The results revealed a significant GSH deficit in FEP patients (0.92 ± 0.24 × 10-3) compared to the healthy control group (1.10 ± 0.10 × 10-3) (U = 25.00, p = 0.02), as well as a positive correlation between GSH levels and the Positive Symptoms subscale of the PANSS in the FEP group (ρ = 0.96; p <0.001). These preliminary findings suggest a possible role of striatal oxidative stress in early-stage psychosis that warrants further scrutiny and confirmation in larger studies.

publication date

  • September 26, 2019

Research

keywords

  • Glutathione
  • Proton Magnetic Resonance Spectroscopy
  • Psychotic Disorders

Identity

Scopus Document Identifier

  • 85071888214

Digital Object Identifier (DOI)

  • 10.1016/j.arcmed.2019.08.003

PubMed ID

  • 31499481

Additional Document Info

volume

  • 50

issue

  • 4